ICIs have become a standard of care in subsets of some tumour types, demonstrating clinically significant benefit in PD-L1-positive metastatic TNBC [14–17] and in early TNBC irrespective of PD-L1 status [18–20], but minimal efficacy in ovarian cancer [21–25]. The gene discussed is CD274; the disease is ovarian cancer.